BHVN
Income statement / Annual
Last year (2023), Biohaven Pharmaceutical Holding Company Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Biohaven Pharmaceutical Holding Company Ltd.'s net income was -$408.17 M.
See Biohaven Pharmaceutical Holding Company Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$462.51 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.37 M |
$1.39 M |
$91.66 M |
$72,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$3.37 M |
-$1.39 M |
$370.85 M |
-$72,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0.8 |
0 |
0 |
0 |
| Research and Development
Expenses |
$373.28 M
|
$437.07 M
|
$181.49 M
|
$98.46 M
|
$344.67 M
|
$0.00
|
| General & Administrative
Expenses |
$56.90 M
|
$130.86 M
|
$37.41 M
|
$16.05 M
|
$134.45 M
|
$0.00
|
| Selling & Marketing
Expenses |
$5.87 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$62.77 M
|
$130.86 M
|
$37.41 M
|
$16.05 M
|
$134.45 M
|
$0.00
|
| Other Expenses |
$0.00 |
-$1.91 M |
$1.21 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$436.05 M |
$567.93 M |
$218.90 M |
$114.51 M |
$479.12 M |
$0.00 |
| Cost And Expenses |
$436.05 M |
$567.93 M |
$218.90 M |
$114.51 M |
$479.12 M |
$0.00 |
| Interest Income |
$17.73 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$12.71 M |
$0.00 |
| Depreciation &
Amortization |
$6.91 M
|
$1.39 M
|
$1.39 M
|
$72,000.00
|
$171,860.00
|
$52,516.00
|
| EBITDA |
-$429.14 M
|
-$462.80 M
|
-$217.51 M
|
-$114.43 M
|
-$479.12 M
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
-0.47 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
-0.47
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$26.50 M
|
-$1.91 M
|
$6.47 M
|
-$4.16 M
|
-$49.26 M
|
$0.00
|
| Income Before Tax |
-$409.55 M |
-$569.84 M |
-$212.43 M |
-$118.67 M |
-$528.39 M |
$0.00 |
| Income Before Tax Ratio
|
0
|
0
|
-0.46
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.38 M |
$438,000.00 |
$1.37 M |
-$134,297.00 |
$419,000.00 |
$0.00 |
| Net Income |
-$408.17 M |
-$570.28 M |
-$213.80 M |
-$118.67 M |
-$528.81 M |
$0.00 |
| Net Income Ratio |
0 |
0 |
-0.46 |
0 |
0 |
0 |
| EPS |
-5.73 |
-12.75 |
-5.97 |
-3.31 |
-10.91 |
0 |
| EPS Diluted |
-5.73 |
-12.75 |
-5.97 |
-3.31 |
-10.91 |
0 |
| Weighted Average Shares
Out |
$71.20 M
|
$44.74 M
|
$35.82 M
|
$35.82 M
|
$48.49 M
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$71.20 M
|
$44.74 M
|
$35.82 M
|
$35.82 M
|
$48.49 M
|
$0.00
|
| Link |
|
|
|
|
|
|
